- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00776113
Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fasting Conditions
An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Carvedilol Formulations Comparing Carvedilol 12.5 mg Tablets of Ranbaxy Laboratories With Coreg® 12.5 mg Tablets of Glaxosmithkline in Healthy, Adult, Human Subjects Under Fasting Conditions
Descripción general del estudio
Descripción detallada
The study was conducted as an open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose, crossover, bioavailability study on carvedilol formulation comparing carvedilol 12.5mg of Ohm Laboratories, Inc. (a subsidiary of Ranbaxy pharmaceuticals Inc, USA) with Coreg® 12.5mg tablet (containing carvedilol 12.5 mg) of GlaxoSmithKline, USA in healthy, adult, male, human subjects under fasting condition.
Forty healthy, adult, human subjects who met the inclusion and exclusion criteria as described in the protocol were enrolled in the study. Thirty-six subjects completed both the periods of the study
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Be in the' age range of 18-45 years.
- Be neither overweight nor underweight for his/her height as per the Life Insurance Corporation of lndia height/weight chart for non-medical cases.
- Have voluntarily given written informed consent to participate in this study.
- Be of normal health as determined by medical history and physical examination of the subjects performed within :1.4 days prior to the commencement of the study.
If female and:
- Of childbearing potential, is practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device ([UD), or abstinence; or Is postmenopausal for at least 1 year; or
- Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
Exclusion Criteria:
- History of allergy to 13-adrenoceptor antagonists especially carvedilol.
- Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations.
- Presence of disease markers of HIV 1 and 2, Hepatitis B and C viruses or syphilis infection.
- Female volunteers demonstrating a positive pregnancy test.
- Female volunteers who are currently breastfeeding.
- Presence of values which are significantly different from normal reference ranges (as defined in Appendix 5) and/or judged clinically significant for haemoglobin, total white blood cells count, differential WBC count or platelet count.
- Positive for urinary screen testing of drugs of abuse (opiates And cannabinoids)
- Presence of values which are significantly different from normal reference ranges (as defined in Appendix 5) and/or judged clinically significant for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or serum cholesterol.
- Clinically abnormal chemical and microscopic examination of urine defined as presence of RBC, WBC (>4/HPF), epithelial cells (>4/HPF), glucose (positive) or protein (positive).
- Clinically abnormal ECG or Chest X-ray.
- History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes, glaucoma, bronchial asthma, fainting or syncope.
- History of any psychiatric illness which may impair the ability to provide written informed consent.
- Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining from smoking for the duration of each study period.
- History of drug dependence or excessive alcohol intake on Habitual basis of more than 2 units of alcoholic beverages per day (1 Unit equivalent to half pint of beer or ! glass of wine or I measure of spirit) or have difficulty_ in abstaininq for the duration of each study period.
- Use of any enzyme modifying drugs within 30 days prior to Day 1 of this study.
- Participation in any clinical trial within 12 weeks preceding Day 1 of this study.
- A haemoglobin concentration of less than 7 % of lower limit of reference range e.g. 13 gm % for reference range of 1448 gm at screening.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: 2
Carvedilol 12.5 mg tablets
|
bioequivalence Carvedilol fasting
|
Experimental: 1
Carvedilol 12.5 mg tablets
|
bioequivalence Carvedilol fasting
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
Bioequivalencia
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Efectos fisiológicos de las drogas
- Beta-antagonistas adrenérgicos
- Antagonistas adrenérgicos
- Agentes adrenérgicos
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Agentes antihipertensivos
- Agentes vasodilatadores
- Agentes Protectores
- Moduladores de transporte de membrana
- Hormonas y agentes reguladores del calcio
- Bloqueadores de los canales de calcio
- Antioxidantes
- Antagonistas de los receptores adrenérgicos alfa-1
- Antagonistas alfa adrenérgicos
- Carvedilol
Otros números de identificación del estudio
- 021/CARVE-12.5/03
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Carvedilol 12.5 mg tablets
-
GlaxoSmithKlineTerminadoEnfermedades del HIGADOJapón
-
Chong Kun Dang PharmaceuticalTerminadoHipertensiónCorea, república de
-
Mylan Pharmaceuticals IncTerminadoSaludableEstados Unidos
-
Mylan Pharmaceuticals IncTerminadoSaludableEstados Unidos
-
IPCA Laboratories Ltd.Terminado
-
GlaxoSmithKlineTerminadoInsuficiencia Cardíaca CongestivaJapón
-
GlaxoSmithKlineTerminado
-
Owen Chan, PhDTerminadoDesconocimiento de la hipoglucemiaEstados Unidos
-
Centre hospitalier de l'Université de Montréal...Activo, no reclutandoRinosinusitis crónica con pólipos nasalesCanadá
-
Yale UniversityNational Institute on Drug Abuse (NIDA)TerminadoDependencia de cocaína | Dependencia de opiáceosEstados Unidos